Our Technology

Chase Biotherapeutics is developing a regenerative therapy platform that addresses one of the major barriers to brain repair after stroke: the glial scar. Our approach combines an engineered enzyme that selectively digests components of the post-stroke extracellular matrix (the Glial border) with a biodegradable hydrogel for local, sustained delivery. By breaking down these inhibitory barriers, the therapy helps to increase plasticity in the brain, making it more permissive for neural regeneration and functional repair.

This disease-modifying technology is designed to restore function by enabling neural repair in chronic stroke patients. Our goal is to bring this first-in-class therapy to the clinic, offering new hope to stroke survivors who currently have no regenerative treatment options, and helping them reclaim their independence, well-being, and quality of life.